Latest Headlines

Latest Headlines

A Phase III win puts Incyte's cancer drug in line for blockbuster status

Incyte CEO Hervé Hoppenot has been telling anyone who'll listen that his biotech is undervalued and underestimated, and now, with promising late-stage results for its lead drug in a rare blood cancer, the company has a shot at blockbuster sales alongside partner Novartis.

With promising Ph3 data in hand, Incyte files for myelofibrosis drug OK

Hot on the heels of detailing promising pivotal data on ruxolitinib, Incyte ($INCY) filed for FDA approval of the myelofibrosis drug. On Saturday investigators for Incyte and Novartis reported that

Novartis maps out a blockbuster future for INC424

With a solid set of favorable late-stage data from two Phase III trials in its hands, Novartis ($NVS) has mapped out a relatively short path to blockbuster status for the experimental cancer drug

Novartis, Incyte ready worldwide apps as cancer drug clears Ph3

An experimental JAK inhibitor under development at Novartis and Incyte hit its primary endpoint in a second late-stage trial, putting the program on track to a second quarter NDA and a possible